Stockreport

Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... [Yahoo! Finance]

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF R&D Expenses: Increased in Q3 2025 compared to Q3 2024, primarily due to the HCV clinical development program. G&A Expenses: Decreased in Q3 2025 compared to Q3 2024, [Read more]